Dynamic Technology Lab Private Ltd trimmed its holdings in Zoetis Inc. (NYSE:ZTS - Free Report) by 80.9% in the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 1,828 shares of the company's stock after selling 7,742 shares during the quarter. Dynamic Technology Lab Private Ltd's holdings in Zoetis were worth $301,000 at the end of the most recent quarter.
Other institutional investors have also made changes to their positions in the company. 1248 Management LLC bought a new position in shares of Zoetis in the first quarter valued at about $27,000. Saudi Central Bank bought a new position in shares of Zoetis in the first quarter valued at about $29,000. Cornerstone Planning Group LLC raised its holdings in shares of Zoetis by 79.3% in the first quarter. Cornerstone Planning Group LLC now owns 199 shares of the company's stock valued at $30,000 after buying an additional 88 shares during the last quarter. Migdal Insurance & Financial Holdings Ltd. raised its holdings in shares of Zoetis by 87.6% in the first quarter. Migdal Insurance & Financial Holdings Ltd. now owns 257 shares of the company's stock valued at $42,000 after buying an additional 120 shares during the last quarter. Finally, Sound Income Strategies LLC raised its holdings in shares of Zoetis by 141.4% in the first quarter. Sound Income Strategies LLC now owns 280 shares of the company's stock valued at $46,000 after buying an additional 164 shares during the last quarter. 92.80% of the stock is owned by institutional investors.
Analyst Ratings Changes
A number of research analysts recently issued reports on the company. Leerink Partnrs cut Zoetis from a "strong-buy" rating to a "hold" rating in a report on Thursday, July 17th. Argus reissued a "buy" rating and set a $190.00 price objective on shares of Zoetis in a report on Tuesday. Leerink Partners cut Zoetis from an "outperform" rating to a "market perform" rating and dropped their price objective for the stock from $180.00 to $155.00 in a report on Thursday, July 17th. Piper Sandler boosted their price objective on Zoetis from $210.00 to $215.00 and gave the stock an "overweight" rating in a report on Monday, August 11th. Finally, Stifel Nicolaus cut Zoetis from a "buy" rating to a "hold" rating and dropped their price objective for the stock from $165.00 to $160.00 in a report on Wednesday, June 18th. Five analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $200.88.
Check Out Our Latest Stock Report on ZTS
Zoetis Price Performance
Zoetis stock opened at $148.33 on Friday. The firm has a market capitalization of $65.74 billion, a P/E ratio of 25.53, a PEG ratio of 2.42 and a beta of 0.89. Zoetis Inc. has a 1 year low of $139.70 and a 1 year high of $200.33. The business has a 50-day moving average of $152.32 and a 200-day moving average of $157.31. The company has a current ratio of 1.76, a quick ratio of 1.04 and a debt-to-equity ratio of 1.05.
Zoetis (NYSE:ZTS - Get Free Report) last posted its earnings results on Tuesday, August 5th. The company reported $1.76 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.62 by $0.14. The company had revenue of $2.46 billion during the quarter, compared to analyst estimates of $2.41 billion. Zoetis had a return on equity of 56.90% and a net margin of 27.83%.The company's revenue for the quarter was up 4.2% compared to the same quarter last year. During the same period in the previous year, the company earned $1.56 EPS. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. On average, equities analysts anticipate that Zoetis Inc. will post 6.07 EPS for the current year.
About Zoetis
(
Free Report)
Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.
Featured Articles
Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Zoetis, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Zoetis wasn't on the list.
While Zoetis currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
